Protagenic Therapeutics (PTIX) Competitors $0.56 +0.04 (+7.69%) (As of 12/17/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsInsider TradesSEC FilingsShort InterestTrends PTIX vs. RLMD, NRXP, AIM, PMCB, TLPH, WENA, IMNN, KZIA, IPA, and AWHShould you be buying Protagenic Therapeutics stock or one of its competitors? The main competitors of Protagenic Therapeutics include Relmada Therapeutics (RLMD), NRx Pharmaceuticals (NRXP), AIM ImmunoTech (AIM), PharmaCyte Biotech (PMCB), Talphera (TLPH), ANEW Medical (WENA), Imunon (IMNN), Kazia Therapeutics (KZIA), ImmunoPrecise Antibodies (IPA), and Aspira Women's Health (AWH). These companies are all part of the "pharmaceutical products" industry. Protagenic Therapeutics vs. Relmada Therapeutics NRx Pharmaceuticals AIM ImmunoTech PharmaCyte Biotech Talphera ANEW Medical Imunon Kazia Therapeutics ImmunoPrecise Antibodies Aspira Women's Health Relmada Therapeutics (NASDAQ:RLMD) and Protagenic Therapeutics (NASDAQ:PTIX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation, media sentiment, institutional ownership and community ranking. Is RLMD or PTIX more profitable? Relmada Therapeutics' return on equity of -129.80% beat Protagenic Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Relmada TherapeuticsN/A -129.80% -112.06% Protagenic Therapeutics N/A -308.97%-228.73% Does the MarketBeat Community believe in RLMD or PTIX? Relmada Therapeutics received 17 more outperform votes than Protagenic Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformRelmada TherapeuticsOutperform Votes1737.78% Underperform Votes2862.22% Protagenic TherapeuticsN/AN/A Do analysts recommend RLMD or PTIX? Relmada Therapeutics presently has a consensus price target of $4.25, indicating a potential upside of 1,075.01%. Given Relmada Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Relmada Therapeutics is more favorable than Protagenic Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Relmada Therapeutics 1 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Protagenic Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has higher valuation and earnings, RLMD or PTIX? Protagenic Therapeutics is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRelmada TherapeuticsN/AN/A-$98.79M-$2.87-0.13Protagenic TherapeuticsN/AN/A-$5M-$1.27-0.44 Does the media favor RLMD or PTIX? In the previous week, Relmada Therapeutics had 1 more articles in the media than Protagenic Therapeutics. MarketBeat recorded 2 mentions for Relmada Therapeutics and 1 mentions for Protagenic Therapeutics. Protagenic Therapeutics' average media sentiment score of 1.44 beat Relmada Therapeutics' score of -0.24 indicating that Protagenic Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Relmada Therapeutics Neutral Protagenic Therapeutics Positive Which has more risk & volatility, RLMD or PTIX? Relmada Therapeutics has a beta of 0.35, meaning that its share price is 65% less volatile than the S&P 500. Comparatively, Protagenic Therapeutics has a beta of 0.21, meaning that its share price is 79% less volatile than the S&P 500. Do insiders & institutionals believe in RLMD or PTIX? 45.2% of Relmada Therapeutics shares are owned by institutional investors. Comparatively, 8.0% of Protagenic Therapeutics shares are owned by institutional investors. 18.0% of Relmada Therapeutics shares are owned by insiders. Comparatively, 37.0% of Protagenic Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. SummaryRelmada Therapeutics beats Protagenic Therapeutics on 10 of the 14 factors compared between the two stocks. Ad Brownstone ResearchDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but designed to power a $9 trillion AI revolution. And I’ve identified a little-known supplier Elon is depending on to make it all happen.I urge you to watch this video now. Get Protagenic Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTIX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PTIX vs. The Competition Export to ExcelMetricProtagenic TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.81M$6.87B$5.18B$9.32BDividend YieldN/A3.06%4.78%4.06%P/E Ratio-0.4410.75128.0017.55Price / SalesN/A288.101,260.27139.72Price / CashN/A56.6541.1637.95Price / Book0.675.394.874.92Net Income-$5M$152.04M$119.61M$225.78M7 Day Performance1.82%-5.54%14.55%-1.48%1 Month Performance-9.39%0.33%17.42%5.36%1 Year Performance-26.28%16.04%35.34%22.71% Protagenic Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PTIXProtagenic Therapeutics1.9806 of 5 stars$0.56+7.7%N/A-26.3%$3.81MN/A-0.441Positive NewsGap UpRLMDRelmada Therapeutics4.3789 of 5 stars$0.48+4.3%$4.25+783.6%-85.4%$14.51MN/A-0.1610Gap DownHigh Trading VolumeNRXPNRx Pharmaceuticals3.0222 of 5 stars$1.20-1.6%$32.00+2,566.7%-95.2%$14.51MN/A0.002Positive NewsGap UpAIMAIM ImmunoTech2.0667 of 5 stars$0.22+6.0%$3.00+1,267.4%-55.5%$13.99M$190,000.00-0.4420News CoverageGap UpPMCBPharmaCyte Biotech1.2285 of 5 stars$1.67+1.8%N/A-22.3%$12.82MN/A2.532Earnings ReportGap DownTLPHTalphera3.6251 of 5 stars$0.75+8.5%$4.50+500.0%N/A$12.77M$650,000.000.0019Positive NewsGap DownWENAANEW MedicalN/A$0.73-0.5%N/AN/A$12.51MN/A0.00N/AGap UpIMNNImunon2.3911 of 5 stars$0.86+2.1%$20.50+2,283.7%-6.2%$12.47M$500,000.000.0033Short Interest ↑KZIAKazia Therapeutics2.3814 of 5 stars$3.70-15.5%$20.00+440.5%-15.0%$12.32M$2.31M0.0012Gap UpIPAImmunoPrecise Antibodies3 of 5 stars$0.42+10.4%$6.00+1,329.9%-68.5%$12.10M$18.16M-0.5880High Trading VolumeAWHAspira Women's Health1.476 of 5 stars$0.72-4.0%$4.40+510.9%-72.5%$12.01M$9.15M0.00110 Related Companies and Tools Related Companies Relmada Therapeutics Alternatives NRx Pharmaceuticals Alternatives AIM ImmunoTech Alternatives PharmaCyte Biotech Alternatives Talphera Alternatives ANEW Medical Alternatives Imunon Alternatives Kazia Therapeutics Alternatives ImmunoPrecise Antibodies Alternatives Aspira Women's Health Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PTIX) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protagenic Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protagenic Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PTIX Stock Alerts